#United States #Boston #Atossa Therapeutics #Steven Quay #ARDD 2026

Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026

Atossa Therapeutics, a clinical-stage biopharmaceutical company, recently announced that its CEO, Dr. Steven Quay, will be speaking at the upcoming Aging Research and Drug Discovery Meeting (ARDD 2026). This conference is set to take place from October 1 to 3, 2026, at the David Rubenstein Treehouse located in Harvard University, Boston, MA.

Overview of the Event

ARDD brings together experts from various fields, including pharmaceuticals, biotechnology, clinical medicine, and academia, all focused on advancing knowledge about aging and age-related diseases. Dr. Quay’s panel discussion will delve into how scientific advances regarding aging can lead to new clinical trials and effective regulatory pathways for novel therapeutics.

Dr. Quay emphasized the significance of strong biological evidence in clinical trial design and how it correlates to regulatory considerations. He stated, "Turning promising science into meaningful therapies requires clinical trials grounded in strong biological evidence and designed with a clear understanding of the regulatory path." This approach is particularly important as Atossa expands its development efforts in the face of rare diseases.

Panel Details

The panel, titled Clinical Trials in Diseases of Aging: From Evidence to New Therapeutics and Regulatory Pathways, will run from 11:20 AM to 12:00 PM ET. Other notable participants include:

• - Jill Lee, Director of Regulatory Policy Intelligence at Novo Nordisk
• - Calum MacRae, Professor at Mass General Brigham
• - Steve Horvath, Professor at UCLA

The co-ordinator for the session will be Sebastien Thuault, Editor at Nature Medicine. This distinguished lineup is expected to foster valuable discussions about the integration of scientific research with clinical applications.

The Importance of Aging Research

As society faces an increasing aging population, the need for effective treatments and regulatory frameworks has never been more critical. The dialogue at ARDD 2026 is vital in translating research findings into actionable therapies. Dr. Quay is eager to share insights and learn from the panel of distinguished leaders.

"The session represents a vital intersection between rapid scientific discovery in aging and the practical considerations required to bring new therapies to the market," said Dr. Quay.

About Atossa Therapeutics

Atossa Therapeutics (Nasdaq: ATOS) is focused on creating innovative medicines in oncology and addressing unmet needs in other healthcare areas. The company’s lead candidate, (Z)-endoxifen, is in various stages of clinical development across several settings.

The therapeutic potential of (Z)-endoxifen lies in its design as a potent Selective Estrogen Receptor Modulator/Degrader (SERM/D), which has shown a favorable safety profile and targets specific mechanisms of action. Currently, it remains unapproved, and Atossa is actively working to establish its applications in both oncology and rare diseases. The program is bolstered by a robust intellectual property portfolio, including several U.S. patents.

In closing, ARDD 2026 offers a platform for dialogue and exploration, fostering collaboration across disciplines with the shared goal of improving health outcomes for an aging population.

For more information on ARDD 2026, visit agingpharma.org.